Thomas E. Stinchcombe, MD

home / authors / thomas-e-stinchcombe-md

Articles

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent

Joe Yujiao Chang, MD, PhD;Larry L. Kestin, MD;R. Bryan Barriger, MD;Indrin J. Chetty, PhD;Mark E. Ginsburg, MD;Sanath Kumar, MD;Billy W. Loo, Jr, MD, PhD;Benjamin Movsas, MD;Andreas Rimner, MD;Kenneth E. Rosenzweig, MD;Thomas E. Stinchcombe, MD;Gregory M. M. Videtic, MD, CM;Henning Willers, MD

August 15th 2014

The treatment of inoperable stage III non–small-cell lung cancer (NSCLC) remains a challenge due to high rates of distant metastasis, local recurrence, and toxicity associated with definitive therapy.

Commentary (Stinchcombe et al): Perspectives on Salvage Therapy for Non–Small-Cell Lung Cancer

Thomas E. Stinchcombe, MD;D. Neil Hayes, MD, MPH;Mark A. Socinski, MD

July 1st 2005

We applaud Dr. Cappuzzo andcolleagues for an excellentreview of an emerging fieldin lung cancer treatment. Since 2000,three drugs (docetaxel [Taxotere],pemetrexed [Alimta], and erlotinib[Tarceva]) have been approved by theUS Food and Drug Administration(FDA) for second-line therapy in non–small-cell lung cancer (NSCLC) basedon the results of phase III trials (seeTable 1).[1-4] It is also possible thatsimilar approval will be sought for otherdrugs (eg, topotecan [Hycamtin]),[5]and gefitinib (Iressa) remains an optionfor treatment in the third-line setting.